MBX Biosciences, a clinical‑stage biopharmaceutical company headquartered in Carmel, Indiana, has appointed Karen Basbaum as its new Chief Business Officer, according to the company. The appointment was announced on March 10, 2026 and follows Basbaum’s more than 20 years of leadership in corporate strategy, business development and strategic transactions within the biotechnology and pharmaceutical industries. The company claims Basbaum’s experience in sourcing, structuring and executing complex partnerships and financings will support advancement of its pipeline of precision peptide therapies for endocrine and metabolic disorders.
Before joining MBX Biosciences, Basbaum served as Senior Vice President of Business Development at Poseida Therapeutics, leading strategic partnerships and corporate transactions, and played a role in the company’s sale to a major pharmaceutical firm. Her prior roles also included leadership positions at DNAtrix, Dauntless Pharmaceuticals and Elcelyx Therapeutics, as well as business development directorship at Amylin Pharmaceuticals. The company states Basbaum holds an MBA from the University of California, Irvine, an M.S. in Organic Chemistry from Rensselaer Polytechnic Institute and dual B.S. degrees in Chemistry and Biology from the University of North Dakota.
According to the company, MBX Biosciences is advancing a pipeline that includes compounds at various stages of clinical development, such as its lead candidate preparing for Phase 3 studies, and additional programs in obesity and post‑bariatric hypoglycemia. The company focuses on therapies developed through its proprietary peptide platform for conditions with unmet medical needs.
